BACKGROUND: The incidence of distant metastases in head and neck cancer patients is rising because of greater locoregional control of the disease. METHODS: The relative risks for having distant metastases as first site of failure relative to the regional lymph node involvement were determined. RESULTS: The overall incidence was 10.7%, with a clear relationship between the number of involved lymph nodes and extranodal spread on one hand, and distant spread on the other hand. The group with histopathologic presence of disease in the neck had twice as much distant metastases as did those with histopathologic absence (13.6% versus 6.9%). Patients with more than three histologically positive lymph nodes were most at risk for having distant metastases (46.8%). The presence of extranodal spread meant a threefold increase in the incidence of distant metastases, compared with patients without this feature (19.1% versus 6.7%). CONCLUSIONS: Patients with three or more positive nodes and with extranodal spread may benefit from adjuvant systemic therapy.
BACKGROUND: The incidence of distant metastases in head and neck cancerpatients is rising because of greater locoregional control of the disease. METHODS: The relative risks for having distant metastases as first site of failure relative to the regional lymph node involvement were determined. RESULTS: The overall incidence was 10.7%, with a clear relationship between the number of involved lymph nodes and extranodal spread on one hand, and distant spread on the other hand. The group with histopathologic presence of disease in the neck had twice as much distant metastases as did those with histopathologic absence (13.6% versus 6.9%). Patients with more than three histologically positive lymph nodes were most at risk for having distant metastases (46.8%). The presence of extranodal spread meant a threefold increase in the incidence of distant metastases, compared with patients without this feature (19.1% versus 6.7%). CONCLUSIONS:Patients with three or more positive nodes and with extranodal spread may benefit from adjuvant systemic therapy.
Authors: Dirk Rades; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Steven E Schild; Christoph Thorns Journal: Strahlenther Onkol Date: 2011-09-19 Impact factor: 3.621
Authors: Jolijn Brouwer; Remco de Bree; Emile F I Comans; Jonas A Castelijns; Otto S Hoekstra; C René Leemans Journal: Eur Arch Otorhinolaryngol Date: 2003-12-17 Impact factor: 2.503
Authors: Russell S Witte; Chandra Karunakaran; Andres N Zuniga; Hannah Schmitz; Hina Arif Journal: Clin Exp Metastasis Date: 2018-08-04 Impact factor: 5.150
Authors: Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li Journal: Int J Cancer Date: 2014-02-27 Impact factor: 7.396